{"id":19479,"date":"2020-12-15T12:19:24","date_gmt":"2020-12-15T11:19:24","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=19479"},"modified":"2021-01-26T11:16:30","modified_gmt":"2021-01-26T10:16:30","slug":"collaboracio-publico-privada-per-a-desenvolupar-un-tractament-per-la-sindrome-x-fragil","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/collaboracio-publico-privada-per-a-desenvolupar-un-tractament-per-la-sindrome-x-fragil\/","title":{"rendered":"Col\u00b7laboraci\u00f3 p\u00fablico-privada per a desenvolupar un tractament per la s\u00edndrome X fr\u00e0gil"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">El consorci publicoprivat format per l\u2019empresa biotecnol\u00f2gica Connecta Therapeutics, el <a rel=\"noreferrer noopener\" href=\"http:\/\/www.crg.eu\/\" target=\"_blank\">Centre de Regulaci\u00f3 Gen\u00f2mica (CRG)<\/a> i l&#8217;<a rel=\"noreferrer noopener\" href=\"http:\/\/www.imim.es\/\" target=\"_blank\">Institut Hospital del Mar d\u2019Investigacions M\u00e8diques&nbsp;(IMIM)<\/a> ha rebut un dels ajuts \u00abReptes Col\u00b7laboraci\u00f3\u00bb 2019 de l&#8217;Ag\u00e8ncia Estatal d&#8217;Innovaci\u00f3, amb un valor <strong>d\u20191,97 milions d\u2019euros<\/strong>, per desenvolupar <strong>un tractament innovador<\/strong> de la <strong><a href=\"https:\/\/ca.wikipedia.org\/wiki\/S%C3%ADndrome_X_fr%C3%A0gil\" target=\"_blank\" rel=\"noreferrer noopener\">s\u00edndrome X fr\u00e0gil (SXF)<\/a>,<\/strong> <strong>la primera causa de discapacitat intel\u00b7lectual heredit\u00e0ria.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aquest ajut se suma als <strong>altres 1,7 milions d\u2019euros<\/strong> que Connecta havia aconseguit d&#8217;una empresa de capital de risc, portant el total a uns 4 milions d\u2019\u20ac.<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>La s\u00edndrome X fr\u00e0gil (SXF) \u00e9s la primera causa de discapacitat intel\u00b7lectual heredit\u00e0ria. El consorci publicoprivat format pel CRG, l&#8217;IMIM i l\u2019empresa Connecta Therapeutics ha aconseguit 4 milions d&#8217;\u20ac per trobar un tractament.<\/p><\/blockquote>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><br>La SXF es deu a una mutaci\u00f3 que<strong> afecta la plasticitat i la maduraci\u00f3 de les connexions sin\u00e0ptiques entre neurones<\/strong>. El <strong>f\u00e0rmac CTH120<\/strong> de Connecta Therapeutics ha demostrat en estudis precl\u00ednics, realitzats al laboratori dirigit per Dierssen, ser un bon modulador d\u2019aquesta neuroplasticitat, al mateix temps que millora la capacitat cognitiva i de conducta social.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ara, el laboratori dirigit per la<strong> <a href=\"https:\/\/ellipse.prbb.org\/ca\/mara-dierssen-crg-ser-cientifica-forma-ser\/\" target=\"_blank\" rel=\"noreferrer noopener\">Mara Dierssen <\/a>al CRG<\/strong>, <a rel=\"noreferrer noopener\" href=\"https:\/\/www.crg.eu\/en\/news\/eu197-million-develop-treatment-fragile-x-syndrome\" target=\"_blank\">realitzar\u00e0 estudis complementaris de farmacologia de la mol\u00e8cula CTH120<\/a>. Posteriorment, l\u2019equip de <strong>Rafael de la Torre a l\u2019IMIM<\/strong> <a rel=\"noreferrer noopener\" href=\"https:\/\/www.imim.cat\/noticies\/937\/connecta-therapeutics-el-crg-i-limim-desenvolupen-un-tractament-innovador-per-a-la-sindrome-x-fragil\" target=\"_blank\">iniciar\u00e0 l&#8217;assaig cl\u00ednic de Fase I, previst per a principis de 2022<\/a>.&nbsp;<br><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Segons els investigadors, col\u00b7laboracions p\u00fablico-privades com aquesta s\u00f3n necessaries per a poder asumir els reptes que implica aquesta recerca translacional.&nbsp; \u00abPer afavorir aquestes col\u00b7laboracions \u00e9s important disposar d&#8217;<strong>instal\u00b7lacions i estructures adequades<\/strong> per a aquest tipus d&#8217;investigaci\u00f3, aix\u00ed com d&#8217;un <strong>equip hum\u00e0 multidisciplinari i amb experi\u00e8ncia<\/strong> en el camp de la <strong>recerca translacional<\/strong>\u00ab, explica Dierssen. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I afegeix de la Torre: \u201cA l&#8217;entorn del <a rel=\"noreferrer noopener\" href=\"http:\/\/www.prbb.org\/ca\" target=\"_blank\">Parc de Recerca Biom\u00e8dica de Barcelona (PRBB)<\/a> es d\u00f3na la possibilitat d&#8217;<strong>abordar des dels estudis precl\u00ednics al desenvolupament cl\u00ednic fins a la <a href=\"https:\/\/ellipse.prbb.org\/ca\/assaigs-clinics-el-llarg-cami-del-desenvolupament-de-nous-farmacs\/\" target=\"_blank\" rel=\"noreferrer noopener\">fase 2<\/a> <\/strong>perqu\u00e8 hi ha un know-how &#8211; en particular sobre discapacitats intel\u00b7lectuals &#8211; que \u00e9s \u00fanic al nostre entorn europeu\u201d.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IMIM i CRG comencen una col\u00b7laboraci\u00f3 amb la biotech Connecta Therapeutics per a desenvolupar un tractament per la primera causa de discapacitat intel\u00b7lectual heredit\u00e0ria.<\/p>\n","protected":false},"author":6,"featured_media":19579,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32],"tags":[651,265,213,726,225,589],"new-type":[35,43],"class_list":["post-19479","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vida-cientifica","tag-assaigs-clinics","tag-crg-ca","tag-imim","tag-innovacio","tag-neurofarmacologia","tag-tecnologia","new-type-noticies","new-type-recomanem"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/19479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=19479"}],"version-history":[{"count":5,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/19479\/revisions"}],"predecessor-version":[{"id":19518,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/19479\/revisions\/19518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/19579"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=19479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=19479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=19479"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=19479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}